South Korea Male Infertility Market

South Korea Male Infertility Market Summary

As per Transpire Insight Analysis the South Korea Male Infertility Market size is estimated at USD 47.52 Million in 2025 and is anticipated to reach USD 64.03 Million by 2033, growing at a CAGR of 3.80% from 2026 to 2033.

South Korea has a business tied to male infertility. It includes hospitals, fertility clinics, testing labs, and drug makers. These groups work on finding and treating male fertility problems. Those issues can make it harder to get pregnant. Common offerings are semen tests and hormone checks. Many clinics also use sperm selection steps, assisted reproduction procedures, and doctor prescribed medicines. The aim is to identify problems that can be treated, then improve the odds of conception.

Over the past few years, the approach has shifted. Clinics now do more than basic semen work. They also add genetic tests and more detailed sperm checks. Some treatment plans are supported by digital tools. This change is tied to falling birth rates in South Korea and shifts in how families form. People have different ideas about when and how they start a family. For that reason, fertility care has drawn more focus.

More money is going toward more accurate testing and targeted care. Clinics can spot male factors sooner, and they can refine the care plan after that. As fertility centers use higher value tests and follow set care routines, the flow of spending changes. More revenue goes to specialist diagnostics, lab services, and reproductive services that rely on tech support. Simple routine testing now makes up a smaller share of income than it used to.

South Korea Male Infertility Market Size & Forecast:

• South Korea Male Infertility Market Size 2025: USD 47.52 Million
• Expected Market Value 2033: USD 64.03 Million
• Forecast CAGR: 3.80%
• Leading region in 2025: 
• Fastest Growing region: 
• Key Profile: Merck KGaA, Ferring Pharmaceuticals, CooperSurgical, Vitrolife, Cook Medical, Irvine Scientific, Organon, Bayer, Pfizer, Eli Lilly, AbbVie, Samsung Medical Center, CHA Medical Group, GC Biopharma, LG Chem Life Sciences 

Key Market Insights

• Seoul and Gyeonggi account for much of the male infertility market in South Korea. In 2025 they are estimated at about 55% share. The area has a thick network of fertility clinics.
• By 2030, growth may pick up faster in Chungcheong and Gyeongsang. Fertility care there is spreading beyond the well known specialist setup in Seoul.
• On the services side, diagnostic and lab work leads. This segment is estimated at roughly 38% share. More people use semen and genetic tests.
• Assisted reproductive services are next. This is still the second largest slice. Male factor cases are moving more often to IUI, IVF, and sperm retrieval steps.
• The quickest growing segment through 2030 is AI assisted sperm analysis. Labs are shifting away from only visual checks under a microscope. They are using automated scoring for form and movement.
• In applications, IVF and ICSI take the top spot. They will make up about 62% share in 2025. More severe male factor cases often need sperm based fertilization.
• Microsurgical sperm retrieval is also rising fast. Advanced sperm selection is growing too. Clinics are dealing with azoospermia and other hard male factor cases.
• For end users, fertility hospitals and specialized reproductive centers lead. They hold about 68% share. These sites tend to run the advanced diagnostic and lab procedures.
• Independent diagnostic labs are growing faster than the rest. Automated semen testing helps labs run quick and repeatable checks outside the main fertility centers.
• CHA Medical Group added more capacity. It opened a Jamsil center in 2024. It also opened a Magok center in 2025.

What are the Key Drivers, Restraints, and Opportunities in the South Korea Male Infertility Market?

South Korea’s male infertility market is getting a lift from policy support and a stronger push for cases tied to male factors. In February 2024, the government removed income eligibility rules. It also combined help for fresh and frozen IVF into a single set of 20 covered cycles. This cut out a lot of upfront cost for patients. In November 2024, HIRA updated the plan again. It moved away from a limit based on the couple and instead used a childbirth allowance. It also reduced the share patients pay for women 45 and older. The rate fell from 50% to 30%. With fewer cost hurdles, more people can start treatment. Fertility hospitals, labs, and diagnostic groups can see better demand and stronger income outlook.

A key drag on growth is how hard some clinical cases can be. Severe male-factor infertility is the main issue, especially non-obstructive azoospermia. Roughly 60% to 70% of azoospermia cases fall into the non-obstructive group. Many patients need microsurgical sperm retrieval. Some also need repeat work in the lab. The process can take longer than basic semen testing. Specialist time and lab work can also raise costs. Another risk is the supply chain. From Transpire Insight’s scan of nearby procurement notices and product start timelines, the supply side is where plans often slip. Specialized lab tools are not always easy to find. There are also not enough highly trained embryologists. This can slow rollouts. It may also limit use outside top cities.

What Has the Impact of Artificial Intelligence Been on the South Korea Male Infertility Market?

AI and digital tools are shifting male fertility care. Many labs used to depend on mostly manual checks. Some clinics are now moving toward more automated steps.Computer vision can read sperm shape and motion from microscope pictures. It can also reduce how much staff must rely on gut feel when they count cells.In South Korea, GoQba Technology built ASMIT with the CHA Fertility Center. The team worked from files on 1,025 men with infertility. They report that review time fell from roughly three to four hours to about 15 seconds.Digital systems can link semen results with other record items. This can include patient traits, prior treatment steps, and lab file details. Then clinicians can scan for patterns that may support a treatment choice and help the lab flow run better.

Researchers are also testing machine-learning models for sperm DNA fragmentation and other reproductive signals. The goal is to look past basic semen measures and add tools that help forecast risk or likely outcomes.Faster day to day review can let labs handle more samples. It can also cut down on repeat manual work. It may help reduce mismatch between observers who score the same samples.Another route is using phone based testing. This could support checks outside the usual lab room. A Korean paper from 2026 reportedly evaluated Hagobogo Pro and compared it with computer assisted sperm analysis.Still, the biggest issue is data quality. AI tools need big datasets that are similar to each other. If clinics use different lab methods, or if shared standard data is hard to find, results can drop when these tools are used in routine care.

Key Market Trends

• Male infertility diagnoses climbed 36.9% between 2020 and 2025. Clinics began to steer more male factor patients into set testing and treatment paths.
• In Feb 2024, reimbursement rules changed. Income limits were removed. Help for fresh and frozen IVF was added into 20 covered cycles.
• In Nov 2024, another update set an IVF coverage cap linked to childbirth. The goal was to keep care aligned for couples who fit the rules.
• In 2025, AI sperm analysis got faster. ASMIT said review time fell from a few hours to about 15 seconds.
• In 2025, CHA opened the Magok fertility center. The plan was to run fertility care at a larger scale, with AI tools included.
• By 2026, more people used phone based semen testing. Hagobogo Pro claimed its readings matched lab computer assisted sperm analysis.
• Researchers also used AI for sperm DNA fragmentation prediction in 2025. The effort went beyond just count, movement, and shape.
• Point of care tests started to show up more often. Spreading them out may reduce how much patients depend on large fertility labs in big cities.
• More clinics are putting several steps together. They link AI sperm work, sperm selection, embryo checks, and digital patient services in one platform.
• In 2025, international partnerships grew as well. Kai Health, for example, worked with Nova IVF in India on AI related fertility tasks.

South Korea Male Infertility Market Segmentation

By Treatment Type : 

Hormonal Therapy helps people who have fertility issues tied to hormone changes. Assisted Reproductive Technology gives medical options when pregnancy does not happen easily on its own. In many fertility clinics, IVF and ICSI are used side by side, depending on what is going on with the male partner. These options are often chosen when infertility links to male-factor concerns. ICSI can be especially useful if sperm numbers are low or if motility is weak. By placing sperm directly for fertilization, it can help the process move forward.

Surgical Treatment is used when there is a physical issue that affects sperm output or how sperm move. Sperm Retrieval is an option for azoospermia or when only a small amount of sperm can be found. Varicocele Treatment focuses on swollen veins that can reduce sperm quality. Antibiotic Therapy is used when reproductive infections are part of the problem. Fertility Supplements are meant to cover nutrition gaps that may affect reproductive health. Some people also need other approaches based on their own medical situation.

By Diagnosis : 

Semen analysis is often the first test. It checks sperm number, movement, and form. With these points, doctors can assess fertility.Blood hormone tests may reveal problems in the hormone system. If hormones are off, sperm production can be affected. Genetic tests are used when there may be an inherited issue linked to infertility.Imaging, like ultrasound, can spot physical problems. 

Some issues can block flow or interfere with reproduction.More clinics are using sperm DNA fragmentation tests. Some doctors want more than the standard semen numbers. A testicular biopsy may be done in certain situations. It lets doctors examine testicular tissue more directly, especially when sperm making is unclear. Other tests may be selected when basic semen results do not fully explain infertility.

By Cause : 

Varicocele is still a major reason for fertility issues. Swollen veins in the testicle area can harm how sperm are made and how well they work. Hormonal Disorders can throw off normal sperm growth. Genetic Disorders may also cause long lasting trouble with sperm production. Infections can injure reproductive tissues. Obstructions can block sperm so they never reach the semen.

Erectile Dysfunction can make natural conception harder even if sperm numbers and function are okay. Low Sperm Count makes fertilization more difficult. It can also push care toward assisted options. When the cause is not clear, doctors need careful clinical checking. Other causes exist too, but they are less common and usually need more focused testing and treatment.

By End User : 

Hospitals provide several kinds of care. Some patients need surgery. Others seek help with fertility. Hospitals also do lab work that backs up treatment decisions.Fertility clinics focus on pregnancy related care. They include lab services as well. Because of that, they often run sperm tests and other steps in fertility plans.Diagnostic centers mainly perform lab checks. Semen analysis is one example. They can also measure hormones. Some sites run genetic tests too. In many cases, these tests are part of fertility checkups.

Specialty clinics handle a smaller set of male health problems. Hormone issues are a common example. Concerns about sexual health may also be treated there. The care is built around those specific conditions.Research institutes work on studies. They also improve lab methods. They test new fertility tools and approaches. Their aim is to track what is developing in this field.Other organizations exist as well. They may offer testing, treatment, and ongoing support for reproductive health.

By Distribution Channel : 

Hospital pharmacies provide fertility medicines and other health items. This is mainly for patients who receive their care in the hospital.Fertility clinics also hand out items that match treatment plans. They may include drugs and supplements, and they may cover certain reproductive procedures.Retail pharmacies serve people who use prescriptions but do not go to the hospital for care. Common examples are antibiotics, hormone products, and fertility supplements.

Online pharmacies can also sell some fertility related items. This fits with how many care services use digital tools now.Specialty pharmacies handle certain products that need extra pharmacy skill and closer monitoring. Some fertility drugs fall in this group.There are more options too. Smaller programs can help people get medicines and fertility products at different care sites.

What are the Key Use Cases Driving the South Korea Male Infertility Market?

Hospitals and fertility clinics are usually the main source of demand for assisted reproductive care. Most of the time this includes IVF and ICSI. But when a couple books a specialist visit, they are not done after the first appointment.They still need lab steps. That can mean semen handling, hormone checks, and help through the treatment period. Because of this, fertility centers end up paying for many items used during each stage.

Diagnostic centers are buying similar tools as well. They do semen analysis and measure hormone levels. Some sites also offer sperm DNA fragmentation testing. A few clinics add extra checks when they think there could be a male hormone issue, a varicocele, or another related problem.

In hospitals, the process often includes planning work. This happens before assisted reproductive procedures get underway.New approaches are also appearing. Some groups are testing AI for sperm imaging reviews. Others are looking at phone based semen testing. Fertility clinics and diagnostic centers may use these ideas to make testing faster and to keep results more consistent from one visit to the next. They may also use online follow up after the main tests so the next steps are simpler.

Which Regions are Driving the South Korea Male Infertility Market Growth?

Seoul leads the region. It makes up around 30% of all fertility-treatment work in the country. This is helped by a high density of specialists and by broader city-level payment support. In 2025, Seoul raised help for infertility care by 24%. That brought the total to 66,906 supported procedures for 26,283 people. Large groups are also based there, including CHA and Maria. They run fertility labs, male infertility services, reproductive preservation, and advanced assisted reproduction units. With strong hospitals in one place, public money, research work, and enough specialists, Seoul is likely to keep its top position through 2033.

Gyeonggi comes next as a major income source. Its services are spread out across nearby satellite cities. This is different from a single core city. The local program covers as many as 25 procedures per birth. It includes IVF and artificial insemination. It also pays for certain related treatment expenses. That setup helps create steady reimbursement. Clinics and hospitals in Suwon, Seongnam, Goyang, Anyang, Bucheon, and other areas make sure people have access in many locations. This wider setup should keep revenue stable as more people in the wider Seoul area seek care.

Chungcheong is being talked about more and more because it is growing fast. In the last few years, the national plan for fertility support has moved past only the largest cities. It also encourages people to get reproductive checkups earlier than before.In 2025, the coverage increased. Fertility testing support was expanded to both men and women from ages 20 to 49. Assistance for preserving reproductive cells was added as well, but it applies only when a medical need is linked to infertility risk.From 2026 through 2033, access to tests could broaden. More specialist services may also arrive. If that happens, fertility clinics, testing labs, and companies tied to related technology could see more work. They may also try to sell and operate in regional areas during that time.

Who are the Key Players in the South Korea Male Infertility Market and How Do They Compete?

The fertility market is not one whole space. Large groups tend to cluster close to university hospitals and specialty clinics. For men with hard fertility problems, cost is rarely the key factor. People who decide on care usually look for better tools, results they can point to from real clinic work, solid lab support, and convenient sites in the right areas.Big firms are moving fast. They add new tech, modernize their labs, and open more clinics. Small companies that supply fertility technology also shift the mix. CHA, Maria, and several university hospitals each show a different path.

CHA Medical Group stands out for its tech focus. It provides IVF that is adjusted for the person. It also covers fertility preservation, along with AI help. CHA backs this with a wide pool of specialists. In 2025, the Magok center opened a new AI fertility unit that spans 6,611 square meters. CHA has also built AI tools to track sperm in difficult samples.Maria Fertility Hospital leans more on steady patient volume and strong lab work. It uses time-lapse methods to choose embryos. It also runs culture systems tuned to reach better results. The hospital offers fertility preservation too. It also expands access via a national branch network. That network added Dongtan in 2025.

Seoul National University Hospital is known for work in urology and medical research. The hospital also treats men who struggle with fertility. Along with this, it provides microsurgery and care for difficult reproductive problems.In the urology program, teams take on complex patient needs. They plan exams first. Then, if surgery is required, they move to the operative part. There are also research staff on site. They coordinate with other specialists when the case needs input from more than one field. INTIN takes a different path. It works on handheld technology for semen checks. Because it connects with fertility groups, some tests can be done outside a typical lab room. This approach can give smaller tech firms room to grow. Faster test turnaround matters. Portability also matters. Use during daily workflows should feel simpler. It is not just about how large a hospital is.

Company List

• Merck KGaA
• Ferring Pharmaceuticals
• CooperSurgical
• Vitrolife
• Cook Medical
• Irvine Scientific
• Organon
• Bayer
• Pfizer
• Eli Lilly
• AbbVie
• Samsung Medical Center
• CHA Medical Group
• GC Biopharma
• LG Chem Life Sciences 

Recent Development News

In January 2025, INTIN launched the HagoBogo at-home sperm observation device at CES 2025, giving men a low-cost way to observe sperm movement through a compact optical system and supporting more accessible fertility screening. 

Source https://www.leading-medicine-guide.com/

In November 2025, CHA Medical Group opened the Magok AI Specialized Global Infertility Center in Seoul, investing in a 6,611-square-meter facility with AI-enabled reproductive systems, an AI egg bank, and advanced laboratory infrastructure to expand technology-driven fertility treatment. Source https://www.mk.co.kr/

What Strategic Insights Define the Future of the South Korea Male Infertility Market?

Over the next five to seven years, the South Korea market for male infertility care may move toward treatment plans made for each person. Clinics may rely more on tech tools. They may also combine newer lab tests with assisted reproduction. Some groups may use AI to look at sperm in a more careful way.One main reason is the need to use treatments with less waste. As fertility care becomes more specific, clinics will want stronger ways to plan visits and choose next steps. At the same time, more government support could help more patients get access to fertility services.

There is another point that matters, even if it is less visible. The market may shift toward larger fertility groups and specialist hospitals. If that happens, smaller firms may struggle to stay competitive.Cost is still a hurdle. Clinical evidence takes time and funding. It can be hard to gather datasets that are consistent across sites. Without shared data, new tools may spread slowly and mainly through a few large centers.

Even so, there may be a chance to grow. AI tools could help find cases of male infertility when no clear cause shows up. Some systems could be trained using clinical records from Asian populations. Early work has already pointed to solid diagnostic results.To stay in the race, companies may need close ties with major fertility hospitals. They may also take part in studies across multiple sites. That could help new tests build real clinical proof. It may also improve how systems connect, and it may help reach areas outside Seoul.

South Korea Male Infertility Market Report Segmentation

By Treatment Type

• Hormonal Therapy
• Assisted Reproductive Technology
• IVF
• ICSI
• Surgical Treatment
• Antibiotic Therapy
• Fertility Supplements
• Sperm Retrieval
• Varicocele Treatment

By Diagnosis

• Semen Analysis
• Hormone Testing
• Genetic Testing
• Ultrasound
• Sperm DNA Fragmentation Testing
• Testicular Biopsy
• Imaging

By Cause

• Varicocele
• Hormonal Disorders
• Genetic Disorders
• Infection
• Obstruction
• Erectile Dysfunction
• Low Sperm Count
• Unknown Causes

By End User

• Hospitals
• Fertility Clinics
• Diagnostic Centers
• Specialty Clinics
• Research Institutes

By Distribution Channel

• Hospital Pharmacies
• Fertility Clinics
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies